Paper17599507
Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer.
Uy KL and 10 others. J Thorac Cardiovasc Surg, 2007. Cited by 66 papers, by iCite.
Cite this record
ConductScience Library. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer. Papers, record 17599507. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17599507
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Cisplatin | |
| Disease-Free Survival | |
| Etoposide | |
| Humans | |
| Lymphatic Metastasis | |
| Male | |
| Middle Aged | |
| Neoplasm Staging | |
| Pneumonectomy | |
| Preoperative Care | |
| Radiotherapy Dosage | |
| Retrospective Studies | |
| Survival Rate |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 18329516 | Mortality associated with pneumonectomy after induction chemoradiation versus chemotherapy alone in stage IIIA-N2 non-small cell lung cancer. | https://conductscience.org/library/papers/18329516 |
Source PubMed
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 66 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42240869 | Prognostic impact of multiple N2 stations in patients with non small cell lung cancer. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42240869 | PubMed |
| 39604439 | Trimodal therapy and surgical approaches in stage IIIA/N2 non-small cell lung cancer. | Sci Rep | 2024 | https://conductscience.org/library/papers/39604439 | PubMed |
| 37980411 | PET/CT based cross-modal deep learning signature to predict occult nodal metastasis in lung cancer. | Nat Commun | 2023 | https://conductscience.org/library/papers/37980411 | PubMed |
| 36761426 | Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers. | Front Oncol | 2022 | https://conductscience.org/library/papers/36761426 | PubMed |
| 36313656 | Preclinical models of radiation-induced cardiac toxicity: Potential mechanisms and biomarkers. | Front Oncol | 2022 | https://conductscience.org/library/papers/36313656 | PubMed |
| 35425698 | Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series. | Front Oncol | 2022 | https://conductscience.org/library/papers/35425698 | PubMed |
| 35207557 | The Potential Role of Nutrition in Lung Cancer Establishment and Progression. | Life (Basel) | 2022 | https://conductscience.org/library/papers/35207557 | PubMed |
| 35048154 | Lung cancer with PET/CT-defined occult nodal metastasis yields favourable prognosis and benefits from adjuvant therapy: a multicentre study. | Eur J Nucl Med Mol Imaging | 2022 | https://conductscience.org/library/papers/35048154 | PubMed |
| 33209872 | Impact of treatment modality on long-term survival of stage IA small-cell lung cancer patients: a cohort study of the U.S. SEER database. | Ann Transl Med | 2020 | https://conductscience.org/library/papers/33209872 | PubMed |
| 31179083 | Novel approach for predicting occult lymph node metastasis in peripheral clinical stage I lung adenocarcinoma. | J Thorac Dis | 2019 | https://conductscience.org/library/papers/31179083 | PubMed |
| 30988393 | Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08). | Br J Cancer | 2019 | https://conductscience.org/library/papers/30988393 | PubMed |
| 30778734 | Keys to successful induction chemoradiotherapy followed by surgery for stage III/N2 non-small cell lung cancer. | Surg Today | 2019 | https://conductscience.org/library/papers/30778734 | PubMed |
| 28603652 | Biopsy and re-biopsy in lung cancer: the oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspiration. | J Thorac Dis | 2017 | https://conductscience.org/library/papers/28603652 | PubMed |
| 27442604 | Five-Year Survival Among Stage IIIA Lung Cancer Patients Receiving Two Different Treatment Modalities. | Med Sci Monit | 2016 | https://conductscience.org/library/papers/27442604 | PubMed |
| 26319488 | The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis. | Ann Thorac Surg | 2015 | https://conductscience.org/library/papers/26319488 | PubMed |
| 25604729 | Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study. | Clin Lung Cancer | 2015 | https://conductscience.org/library/papers/25604729 | PubMed |
| 24722151 | National patterns of care and outcomes after combined modality therapy for stage IIIA non-small-cell lung cancer. | J Thorac Oncol | 2014 | https://conductscience.org/library/papers/24722151 | PubMed |
| 24163751 | Surgery in 2013 and beyond. | J Thorac Dis | 2013 | https://conductscience.org/library/papers/24163751 | PubMed |
| 23436118 | Current status and perspective of EBUS-TBNA. | Gen Thorac Cardiovasc Surg | 2013 | https://conductscience.org/library/papers/23436118 | PubMed |
| 22853619 | Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients. | BMC Complement Altern Med | 2012 | https://conductscience.org/library/papers/22853619 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17599507
GET https://conductscience.org/api/papers/v1/17599507/cited_by?page=2